Huang CY - Search Results

1

Propensity score matching analysis comparing radical prostatectomy and radiotherapy with androgen deprivation therapy in locally advanced prostate cancer.

Lu YC, Huang CY, Cheng CH, Huang KH, Lu YC, Chow PM, Chang YK, Pu YS, Chen CH, Lu SL, Lan KH, Jaw FS, Chen PL, Hong JH. Lu YC, et al. Among authors: huang kh, huang cy. Sci Rep. 2022 Jul 21;12(1):12480. doi: 10.1038/s41598-022-16700-7. Sci Rep. 2022. PMID: 35864293 Free PMC article.

2

Curcumin enhances cytotoxicity of chemotherapeutic agents in prostate cancer cells by inducing p21(WAF1/CIP1) and C/EBPbeta expressions and suppressing NF-kappaB activation.

Hour TC, Chen J, Huang CY, Guan JY, Lu SH, Pu YS. Hour TC, et al. Among authors: huang cy. Prostate. 2002 May 15;51(3):211-8. doi: 10.1002/pros.10089. Prostate. 2002. PMID: 11967955

3

Arsenic trioxide as a novel anticancer agent against human transitional carcinoma--characterizing its apoptotic pathway.

Pu YS, Hour TC, Chen J, Huang CY, Guan JY, Lu SH. Pu YS, et al. Among authors: huang cy. Anticancer Drugs. 2002 Mar;13(3):293-300. doi: 10.1097/00001813-200203000-00011. Anticancer Drugs. 2002. PMID: 11984073

4

Cytotoxicity of arsenic trioxide to transitional carcinoma cells.

Pu YS, Hour TC, Chen J, Huang CY, Guan JY, Lu SH. Pu YS, et al. Among authors: huang cy. Urology. 2002 Aug;60(2):346-50. doi: 10.1016/s0090-4295(02)01699-0. Urology. 2002. PMID: 12137851

5

Characterization of molecular events in a series of bladder urothelial carcinoma cell lines with progressive resistance to arsenic trioxide.

Hour TC, Huang CY, Lin CC, Chen J, Guan JY, Lee JM, Pu YS. Hour TC, et al. Among authors: huang cy. Anticancer Drugs. 2004 Sep;15(8):779-85. doi: 10.1097/00001813-200409000-00007. Anticancer Drugs. 2004. PMID: 15494640

6

Epidermal growth factor receptor inhibitor (PD168393) potentiates cytotoxic effects of paclitaxel against androgen-independent prostate cancer cells.

Pu YS, Hsieh MW, Wang CW, Liu GY, Huang CY, Lin CC, Guan JY, Lin SR, Hour TC. Pu YS, et al. Among authors: huang cy. Biochem Pharmacol. 2006 Mar 14;71(6):751-60. doi: 10.1016/j.bcp.2005.12.009. Epub 2006 Jan 18. Biochem Pharmacol. 2006. PMID: 16413505

7

Weekly cisplatin plus infusional high-dose 5-fluorouracil and leucovorin (P-HDFL) for metastatic urothelial carcinoma: an effective regimen with low toxicity.

Lin CC, Hsu CH, Huang CY, Cheng AL, Chen J, Vogelzang NJ, Pu YS. Lin CC, et al. Among authors: huang cy. Cancer. 2006 Mar 15;106(6):1269-75. doi: 10.1002/cncr.21738. Cancer. 2006. PMID: 16470604 Free article. Clinical Trial.

8

Differential expression of molecular markers in arsenic- and non-arsenic-related urothelial cancer.

Hour TC, Pu YS, Lin CC, Huang SW, Chen J, Chiu AW, Chen CJ, Huang CY. Hour TC, et al. Among authors: huang sw, huang cy. Anticancer Res. 2006 Jan-Feb;26(1A):375-8. Anticancer Res. 2006. PMID: 16475721 Free article.

9

Primary amyloidosis of the urinary bladder.

Huang CY, Shun CT, Huang KH, Chen J, Pu YS. Huang CY, et al. Among authors: huang kh. J Formos Med Assoc. 2006 Feb;105(2):164-7. doi: 10.1016/S0929-6646(09)60339-9. J Formos Med Assoc. 2006. PMID: 16477338 Free article.

10

Association of vitamin D receptor FokI polymorphism with prostate cancer risk, clinicopathological features and recurrence of prostate specific antigen after radical prostatectomy.

Huang SP, Huang CY, Wu WJ, Pu YS, Chen J, Chen YY, Yu CC, Wu TT, Wang JS, Lee YH, Huang JK, Huang CH, Wu MT. Huang SP, et al. Among authors: huang jk, huang ch, huang cy. Int J Cancer. 2006 Oct 15;119(8):1902-7. doi: 10.1002/ijc.22053. Int J Cancer. 2006. PMID: 16708371 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

4,490 results

Search Page